Investment Opportunity in Nanotechnology-based Cancer Drug Development
The private placement round is open until the end of April 2024
ABOUT iNANOD
iNANOD AS is a privately owned start-up company grown through the pull mechanism of innovation from the Oslo Cancer Cluster Incubator. iNANOD utilizes nano-biotechnology to establish a platform to improve drug delivery, especially within oncology. It has the ambition to deliver the active pharma ingredient in a targeted and accelerated way while generating immunotherapy. Therefore envisioning to kill cancer cells target-specifically by combined double actions of chemo and immunotherapy in solid malignant tumours.
THE PROBLEM
As per the World Health Organization, 9.6 million people died from cancer in 2018 (1 out of 6 deaths worldwide). Today, cancer patients suffer from a high rate of undesired side effects while under chemotherapy. Most cancer drugs are not site-specific.
Max 0.2% of small molecule cancer drugs reach cancer cells, while the rest spread over the body and impart unintended adverse effects on healthy cells.
THE SOLUTION
An innovative platform technology for cancer drug-delivery with the potential to disrupt the cancer drugs market.
​
iNANOD's technology combines individually proven technologies to improve drug delivery and reduce side effects.
​
We detected the need to incorporate cutting-edge technology in modern cancer treatments and aims to add value by introducing accelerated uptake involving a time parameter.
​
Our objective is to develop a platform technology for shorter chemotherapy with fewer side effects.
OUR PROPOSAL
THE TEAM
Åge Nærdal
Chairman
Trained as a Pharmacist having more than 35 years of experience in leadership from pharmaceutical industry.
Stener Kvinnsland
Board member
MD with a PhD in oncology. Various roles in the pharmaceutical and biotech industry, former COB at Oslo University Hospital, former MD of Helse Bergen and former Director at Haukeland University Hospital. Specialist and professor in cancer medicine.
Per Foss
Board member
Bio-organic chemistry doctorate having hugely diverse professional expertise in the industry.
Nalinava Sengupta
Board Member & CEO
After 15 years of academic research in chemistry, turned entrepreneur for a mission.
Thomas Due
Board member
He has over 20 years of Innovation and Venture Capital Fundraising experience in Norway. He has spent most of his adult life working where finance meets entrepreneurs.
ADVISORS
Knut Smerud
Advisory Board Member
-
Tanima Sengupta
Advisory Board Member
Co-founder and is a senior scientist in Norwegian Air Research Institute
Gokce Ataman
Financial Advisor
Senior finance professional with over 15 years of experience in M&A advisory and asset management.
Jørn Lein-Mathisen
Business Development Advisor
Business angel. Business development and entrepreneurial experiences internationally over 28 years.
Hilde Nilsen
Board member
Head of researchDepartment of Microbiology, Oslo University Hospital
Espen Burum-Auensen
Advisory Board Member
Medical doctor with a PhD in the field of oncology. Various roles in the pharmaceutical and biotech industry including business development, clinical trial development, commercial operations, and medical affairs.
Ketil Wig
Strategic Advisor
An expert in strategy and corporate finance advisory, has executed and negotiated hundreds of projects and transactions within strategy and M&A and restructurings / turnarounds.
Hilde Morris
Scientific Advisor
Studied veterinary medicine and led international clinical development programs. Advices iNANOD for pre-clinical research, management, and corporate governance.
_edited_edited.jpg)
Bruno Pirovino-Zuercher
Fund-raising Advisor
Finance Executive with over 25 years of experience in global LifeScience organisations and start/scale-up companies; Angel Investor
SUPPORTERS
MEMBER OF
SUBCONTRACTORS
FUNDRAISING ROUND AND PURPOSE
iNANOD is raising USD 1.4 million at a pre-money valuation of USD 4.0 million.
​
The Company previously raised ca. USD 0.5 million led by business angels.
​
In this round, iNANOD is selling shares at a price of USD 1.08 per share.
If iNANOD is successful in reaching PoP, the Company will engage in further fundraising to fund regulatory preclinical development, phase I and phase II clinical trials, with a view to entering into a licensing deal with Big Pharma after phase IIb. A typical licensing deal includes an upfront payment, milestone payments, and royalty fees.
CONTACT
TAKE THE NEXT STEP
For detailed information please get in
touch with iNANOD at:
If you’re interested in investing in iNANOD, please enter your contact information below. We’ll get in touch with you.
iNANOD AS c/o VENTURELAB
Nedre Skøyen vei 11,
Oslo, Norway
0276
+47 938 13 586